Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart has believes that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Its development programs currently include tablet vaccines designed to protect against coronavirus, Norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immuno-oncology indication. Vaxart has filed broad domestic and international patents covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

Company profile
Ticker
VXRT
Exchange
Website
CEO
Andrei Floroiu
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Exelixis • Sana Biotechnology • Ginkgo Bioworks • Bio-Techne ...
Former names
Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., NABI BIOPHARMACEUTICALS, NABI /DE/, NABI BIOPHARMACEUTICALS, NORTH AMERICAN BIOLOGICALS INC
SEC CIK
Corporate docs
Subsidiaries
Vaxart Biosciences, Inc. • Biota Holdings • Biota Scientific Management Pty, Ltd. ...
IRS number
591212264
VXRT stock data
News
Vaxart Q2 EPS $(0.23) Misses $(0.21) Estimate
8 Aug 22
Vaxart Initiates Work on Vaccine Candidates That Directly Target New Omicron Variants of Concern
8 Aug 22
Earnings Scheduled For August 8, 2022
8 Aug 22
Recap of Wednesday's Biotech Catalysts - End of The Day Summary
20 Jul 22
Vaxart Publishes Clinical Data Suggesting Its Oral COVID-19 Pill Vaccine Candidate Induces Long-Lasting Mucosal Immune Responses That Are Highly Cross-Reactive
20 Jul 22
Press releases
Vaxart Provides Business Update and Reports Second Quarter 2022 Financial Results
8 Aug 22
Vaxart Stockholders Approve Proxy Proposals 2, 3 and 4
5 Aug 22
Vaxart to Host Second Quarter 2022 Business Update and Financial Results Conference Call on August 8
28 Jul 22
Vaxart to Present Preclinical and Clinical Data From Its COVID-19 Oral Tablet Vaccine Program at ICMI 2022
14 Jul 22
Thinking about trading options or stock in DoorDash, Merck, General Mills, Apple, or Vaxart?
6 Jul 22
Analyst ratings and price targets
Calendar
8 Aug 22
16 Aug 22
31 Dec 22
Financial summary
Quarter (USD) | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 91.47M | 91.47M | 91.47M | 91.47M | 91.47M | 91.47M |
Cash burn (monthly) | 10.65M | 6.15M | 9.81M | 8.02M | 8.63M | 6.76M |
Cash used (since last report) | 16.73M | 9.66M | 15.41M | 12.61M | 13.57M | 10.62M |
Cash remaining | 74.74M | 81.8M | 76.06M | 78.86M | 77.9M | 80.85M |
Runway (months of cash) | 7.0 | 13.3 | 7.8 | 9.8 | 9.0 | 12.0 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
4 Aug 22 | Julie M Cherrington | Common Stock | Grant | Acquire A | No | No | 0 | 6,217 | 0 | 6,217 |
4 Aug 22 | Julie M Cherrington | Stock Option Common Stock | Grant | Acquire A | No | No | 3.91 | 37,280 | 145.76K | 37,280 |
4 Aug 22 | Davis Todd C | Common Stock | Grant | Acquire A | No | No | 0 | 7,375 | 0 | 125,905 |
4 Aug 22 | Davis Todd C | Stock Option Common Stock | Grant | Acquire A | No | No | 3.91 | 44,224 | 172.92K | 44,224 |
4 Aug 22 | Finney Michael J. | Common Stock | Grant | Acquire A | No | No | 0 | 7,375 | 0 | 663,465 |
4 Aug 22 | Finney Michael J. | Stock Option Common Stock | Grant | Acquire A | No | No | 3.91 | 44,224 | 172.92K | 44,224 |
4 Aug 22 | Wheadon David E. | Common Stock | Grant | Acquire A | No | No | 0 | 7,375 | 0 | 7,375 |
4 Aug 22 | Wheadon David E. | Stock Option Common Stock | Grant | Acquire A | No | No | 3.91 | 44,224 | 172.92K | 44,224 |
Institutional ownership, Q1 2022
35.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 144 |
Opened positions | 22 |
Closed positions | 25 |
Increased positions | 42 |
Reduced positions | 47 |
13F shares | Current |
---|---|
Total value | 281.94M |
Total shares | 44.92M |
Total puts | 521.2K |
Total calls | 1.14M |
Total put/call ratio | 0.5 |
Largest owners | Shares | Value |
---|---|---|
STT State Street | 13.86M | $69.86M |
BLK Blackrock | 8.44M | $42.55M |
Vanguard | 6.07M | $30.62M |
Geode Capital Management | 2.23M | $11.26M |
D. E. Shaw & Co. | 1.59M | $8.03M |
MS Morgan Stanley | 1.25M | $6.31M |
NTRS Northern Trust | 1.2M | $6.03M |
Rafferty Asset Management | 996.46K | $5.02M |
Charles Schwab Investment Management | 905.31K | $4.56M |
UBS UBS Group AG - Registered Shares | 836.82K | $4.22M |
Financial report summary
?Competition
PDS BiotechnologyContent analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
aforementioned, American, animal, appeal, back, BioDelivery, career, Central, Chair, Chairperson, client, CMO, conclusion, construct, contest, Deloitte, disagreement, doubling, ESPP, Exhibit, expertise, family, fill, Florida, Fortune, hamster, hearing, hereto, hinder, inability, Institute, interval, Isicrate, journal, Karen, lapsed, Leader, listing, Marketplace, Marquette, Medicine, medRxiv, member, middle, mixture, Nasdaq, Omicron, parental, path, Paul, pharmaceutical, predecessor, proposed, qualified, reached, recommendation, Regulation, reject, resign, resignation, Restated, revert, Robert, science, Secretary, shifted, shorter, slightly, sooner, spent, Stipulation, successor, thereof, Tohmatsu, Touche, Translational, trending, undergraduate, unpaid, vacancy, variant, vigorously, Watson, Wilson, Yedid, younger
Removed:
anticipated, capture, Chief, European, factor, gained, growth, Importantly, operate, President, Shionogi, topline, unvaccinated
Financial reports
Current reports
8-K
Vaxart Provides Business Update and Reports Second Quarter 2022 Financial Results
8 Aug 22
8-K/A
Vaxart Stockholders Approve Proxy Proposals 2, 3 and 4
5 Aug 22
8-K
Other Events
28 Jul 22
8-K
Submission of Matters to a Vote of Security Holders
8 Jul 22
8-K
Entry into a Material Definitive Agreement
6 Jul 22
8-K
Other Events
28 Jun 22
8-K
Management to discuss progress on its programs, annual stockholders’ meeting proposals
16 Jun 22
8-K
Vaxart Announces Adjournment of Annual Meeting of Stockholders
8 Jun 22
8-K
Other Events
6 Jun 22
8-K
Departure of Directors or Certain Officers
11 May 22
Registration and prospectus
424B5
Prospectus supplement for primary offering
15 Sep 21
424B5
Prospectus supplement for primary offering
15 Sep 21
S-8
Registration of securities for employees
21 Jun 21
424B5
Prospectus supplement for primary offering
13 Oct 20
S-3ASR
Automatic shelf registration
8 Jul 20
S-8
Registration of securities for employees
7 Jul 20
424B5
Prospectus supplement for primary offering
2 Mar 20
424B4
Prospectus supplement with pricing info
27 Sep 19
POS AM
Prospectus update (post-effective amendment)
27 Sep 19
FWP
Free writing prospectus
25 Sep 19
Proxies
DEFA14A
Additional proxy soliciting materials
26 Jul 22
DEFA14A
Additional proxy soliciting materials
26 Jul 22
DEFA14A
Additional proxy soliciting materials
12 Jul 22
DEFA14A
Additional proxy soliciting materials
1 Jul 22
DEFA14A
Additional proxy soliciting materials
1 Jul 22
DEFA14A
Additional proxy soliciting materials
24 Jun 22
DEFA14A
Additional proxy soliciting materials
25 May 22
DEFA14A
Additional proxy soliciting materials
18 May 22
DEFA14A
Additional proxy soliciting materials
28 Apr 22
DEF 14A
Definitive proxy
28 Apr 22
Other
UPLOAD
Letter from SEC
28 Jan 21
CORRESP
Correspondence with SEC
26 Jan 21
UPLOAD
Letter from SEC
21 Jan 21
CORRESP
Correspondence with SEC
7 Jan 21
UPLOAD
Letter from SEC
27 Dec 20
EFFECT
Notice of effectiveness
3 Oct 19
EFFECT
Notice of effectiveness
27 Sep 19
CORRESP
Correspondence with SEC
25 Sep 19
CORRESP
Correspondence with SEC
25 Sep 19
CORRESP
Correspondence with SEC
22 Sep 19
Ownership
4
Vaxart / W. Mark Watson ownership change
8 Aug 22
4
Vaxart / Robert A. Yedid ownership change
8 Aug 22
4
Vaxart / David E. Wheadon ownership change
8 Aug 22
4
Vaxart / Michael J. Finney ownership change
8 Aug 22
4
Vaxart / Todd C Davis ownership change
8 Aug 22
4
Vaxart / Julie M Cherrington ownership change
8 Aug 22
3
Vaxart / W. Mark Watson ownership change
8 Aug 22
4
Vaxart / Fuad Ahmad ownership change
23 Jun 22
3
Vaxart / Fuad Ahmad ownership change
12 May 22
4
Vaxart / Sean Tucker ownership change
25 Apr 22
Transcripts
Reddit threads
Daily Discussion Thread - August 5th, 2022
5 Aug 22
What Are Your Moves Tomorrow - July 29, 2022
28 Jul 22
vaxart $vxrt mentioned at White House summit
27 Jul 22
vaxart $vxrt mentioned at White House summit
27 Jul 22
vaxart mentioned at White House vaccine summit $vxrt
27 Jul 22
vaxart $vxrt may be discussed here
25 Jul 22
vaxart? $vxrt
25 Jul 22
vaxart? $vxrt
25 Jul 22
Did someone say $vxrt?
25 Jul 22
Vaxart : Oral Tablet Vaccination to SARS-CoV-2 Induces Pan-coronavirus Nasal IgA Responses in Humans by Dr Tucker | MarketScreener $vxrt
19 Jul 22